| Accession Number: | 0001209191-23-015865 |
| Date: | 2023-03-01 |
| Issuer: | KINNATE BIOPHARMA INC. (KNTE) |
| Original Submission Date: |
DESIMONE JILL
103 MONTGOMERY STREET, SUITE 150
THE PRESIDIO OF SAN FRANCISCO
SAN FRANCISCO, CA 94129
| Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
|---|
| Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STOCK OPTION (RIGHT TO BUY) | 5.21 | 2023-03-01 | deemed execution date | A | 50,000 (a) | 2033-03-01 | common stock 50,000 | $5.21 | 50,000 | direct |
| ID | footnote |
|---|---|
| f1 | 1/36th of the shares underlying the option vest and become exercisable on each monthly anniversary of the date of grant. |
